USA – Uqora, a leader in urinary tract health products, has grown rapidly as a leading biotechnology company.
Since its founding in 2017, Uqora has been at the forefront of urinary health research, developing products for proactive urinary tract health and UTI relief. he company is on track for continued growth in 2020 with ongoing clinical trials and another product expansion under its belt. Uqora is steadfast in its vision for the future of urinary tract health, one that includes well-funded research that furthers the development of prevention methods and finds alternative treatments to help those suffering from vicious UTI cycles. Urinary
tract infections are one of the most common infections, with a lifetime incidence rate of 50-60% among adult women. Uqora has
designed products that address UTIs both through proactive urinary tract health
supplements as well as point-of-need products for active infections. In search
of an end to her own cycle of recurring UTIs, founder Jenna Ryan along with her
partner Spencer Gordon sought out urologists and physicians to develop Uqora’s
effective, science-backed products. Today, Uqora has become an innovative
biotech company helping lead urinary health research.A Snapshot of Uqora’s GrowthUqora
has helped over 100,00 women struggling with UTIs since its launch three years
ago. Uqora products are available only on Uqora.com, making its revenues 100%
direct-to-consumer. Uqora products can be purchased individually or through a
subscription. As a subscription-driven product, 70% of new customers purchase a
subscription, and subscription renewals and purchases make up 80% of monthly
revenues for the company. Having grown 14 times its size in 2018 and 5 times in
2019, the biotechnology company is set to grow almost 3 times as large in 2020.
Despite
its quick growth, Uqora was initially started only with capital invested by the
founders. Then, friends and family raised a small amount of capital which funded
the company over the following 18 months. Uqora closed a seed round in Q4 of
2018. The company now has a strong growth trajectory and is profitable, but has
yet to raise Series A funding. Uqora understands that its growth is attributed
to strong customer service, outstanding retention rates, and effective
products. Uqora
boasts over 5,00 five-star customer reviews, proving that their products have
helped thousands of people find relief from a painful cycle of UTIs. Uqora
products can be purchased individually or in kits. Due to the nature of UTI
prevention, many sign up for Uqora subscriptions so that customers always have
proactive supplements available. Because Uqora only sells its products directly
from its own website, it makes the consumer experience a breeze. Users can take
a short quiz to find out which products would best meet their needs, and all
the product information is readily available on the site. This kind of
transparency has contributed to a strong relationship between company and consumer
which translates into high customer retention rates.The Beginning: Early Funding EffortsUqora
has come far since its inception. In 2014, Jenna Ryan struggled with recurrent
UTIs that inspired her to find relief when no other methods were effective. Along
with co-founder Spencer Gordon, whose background is in biochemistry, they
teamed up with urologists to create a product that would bring effective
urinary health solutions to thousands. With
urinary tract infections being so ubiquitous, the demand for effective
alternatives was there. Eventually, the company closed a round of seed funding
in 2018.New Growth Leads to Expanded Product OfferingsWhat
began as one proactive care product has
grown to a line of three, along with UTI diagnostics and over-the-counter
products that target active infections. The first product created was Target, a drink powder using D-mannose, a
sugar commonly used in the prevention of UTIs, and other active ingredients to
flush the urinary tract. After some success with the first product, Ryan
surveyed existing customers and found many still needed a more proactive
preventative measure to safeguard against recurrent UTIs. This led to the
release of Uqora’s supplement pill, Control,
taken daily to cleanse biofilm from the urinary tract. The third product
introduced was Promote, a vaginal probiotic.Uqora
now offers a 3-step proactive urinary tract supplement system to help maintain
urinary health. Earlier this year, Uqora launched three UTI
relief products
aimed at addressing concerns for those with active UTIs. These products include
diagnostic test strips so users can conclude
if they have a UTI, and two over-the-counter products for pain relief
and infection control. The introduction of these three new products means Uqora
products now tackle urinary tract infections end-to-end. Customers can turn to
Uqora for a proactive approach to urinary health , as well as diagnostics and
symptom relief so that they’re more prepared when visiting their health care
provider for UTI treatment. Over the last three years, Uqora has grown into a
one-stop-shop for Urinary tract health,, UTI diagnostics, and
relief. Growth in Research, Clinical TrialsAside
from expanding their product offerings, Uqora’s growth in funding has enabled
the company to launch several clinical
trials. These clinical trials with research groups Hawthorne Effect and the
George Washington University Medical Faculty Associates Urology Clinic will
test the efficacy of Uqora’s products. Both clinical trials will
expand research
for women’s urinary tract health, as well as help Uqora improve their product
offering, ensuring customers have the best preventative UTI products available.
Uqora has used its growth to further its mission to provide innovative and
effective alternative solutions for those who suffer from recurring UTIs. The
Hawthorne Effect clinical trial will take place over 180 days, with results
available in the second half of 2020. The George Washington University clinical
trial began in 2020 and will last 12 months. Both are randomized, double-blind,
placebo-controlled studies carried out by third-party labs, ensuring
trustworthy results. Without Uqora’s revenue growth and profitability, such
research would not be possible. Development of Non-Antibiotic TreatmentUTIs
are typically treated with antibiotics, despite the fact that the number of
antibiotic-resistant UTIs has doubled in the last 10 years. According to the
CDC, 30% of prescribed antibiotics are
unnecessary. Antibiotic resistance can also lead to a cycle of recurring
urinary tract infections. However, as public concern about antibiotic
resistance begins to grow, many are in search of effective alternatives. With
few answers outside of already established treatments, Uqora has been able to
capture a market ripe for innovation. This has allowed the company to continue
investing in research, testing its own products to ensure their effectiveness,
and growing its product offerings. Women’s
urinary health issues have long been underfunded and under-researched. Ryan
believes in the importance of contributing to scientific research involving
women’s health issues. It is this belief that motivates Uqora’s founders to
work towards creating options for those seeking UTI treatment alternatives.
Ever the leading innovators in the urinary tract health space, Uqora is working
to develop a new, non-antibiotic UTI treatment option for those seeking an
alternative to traditional antibiotic remedies.Uqora’s Innovative FutureUqora’s
impressive growth over the last three years has opened many avenues for the
young company. By prioritizing excellent customer service and providing
effective UTI solutions that lead to high customer retention rates, Uqora has
been able to expand its line of products, make strides in urinary health
research, and fund clinical trials. The company is also working to make
innovative strides in alternative UTI treatment solutions that address
antibiotic resistance. Uqora’s goal is to eventually develop an effective UTI
treatment option that does not require the use of antibiotics.Uqora
began out of necessity when Ryan was trapped in a recurring and painful UTI
cycle back in 2014. From that small founder and family funded venture, Uqora
has grown into a breakthrough biotechnology company, investing funding dollars
into women’s urinary health research and reimagining what it means to tackle
urinary tract health in a field where such research is often overlooked and
underfunded. As Uqora continues to grow, so will its reach and impact. Uqora
has already helped over 100,000 people struggling with recurring UTI
infections, and the company is still showing steady growth. Its emphasis on
research and development, paired with a mission to bring effective proactive
UTI prevention methods to all, makes Uqora a cutting-edge company to watch.
tract infections are one of the most common infections, with a lifetime incidence rate of 50-60% among adult women. Uqora has
designed products that address UTIs both through proactive urinary tract health
supplements as well as point-of-need products for active infections. In search
of an end to her own cycle of recurring UTIs, founder Jenna Ryan along with her
partner Spencer Gordon sought out urologists and physicians to develop Uqora’s
effective, science-backed products. Today, Uqora has become an innovative
biotech company helping lead urinary health research.A Snapshot of Uqora’s GrowthUqora
has helped over 100,00 women struggling with UTIs since its launch three years
ago. Uqora products are available only on Uqora.com, making its revenues 100%
direct-to-consumer. Uqora products can be purchased individually or through a
subscription. As a subscription-driven product, 70% of new customers purchase a
subscription, and subscription renewals and purchases make up 80% of monthly
revenues for the company. Having grown 14 times its size in 2018 and 5 times in
2019, the biotechnology company is set to grow almost 3 times as large in 2020.
Despite
its quick growth, Uqora was initially started only with capital invested by the
founders. Then, friends and family raised a small amount of capital which funded
the company over the following 18 months. Uqora closed a seed round in Q4 of
2018. The company now has a strong growth trajectory and is profitable, but has
yet to raise Series A funding. Uqora understands that its growth is attributed
to strong customer service, outstanding retention rates, and effective
products. Uqora
boasts over 5,00 five-star customer reviews, proving that their products have
helped thousands of people find relief from a painful cycle of UTIs. Uqora
products can be purchased individually or in kits. Due to the nature of UTI
prevention, many sign up for Uqora subscriptions so that customers always have
proactive supplements available. Because Uqora only sells its products directly
from its own website, it makes the consumer experience a breeze. Users can take
a short quiz to find out which products would best meet their needs, and all
the product information is readily available on the site. This kind of
transparency has contributed to a strong relationship between company and consumer
which translates into high customer retention rates.The Beginning: Early Funding EffortsUqora
has come far since its inception. In 2014, Jenna Ryan struggled with recurrent
UTIs that inspired her to find relief when no other methods were effective. Along
with co-founder Spencer Gordon, whose background is in biochemistry, they
teamed up with urologists to create a product that would bring effective
urinary health solutions to thousands. With
urinary tract infections being so ubiquitous, the demand for effective
alternatives was there. Eventually, the company closed a round of seed funding
in 2018.New Growth Leads to Expanded Product OfferingsWhat
began as one proactive care product has
grown to a line of three, along with UTI diagnostics and over-the-counter
products that target active infections. The first product created was Target, a drink powder using D-mannose, a
sugar commonly used in the prevention of UTIs, and other active ingredients to
flush the urinary tract. After some success with the first product, Ryan
surveyed existing customers and found many still needed a more proactive
preventative measure to safeguard against recurrent UTIs. This led to the
release of Uqora’s supplement pill, Control,
taken daily to cleanse biofilm from the urinary tract. The third product
introduced was Promote, a vaginal probiotic.Uqora
now offers a 3-step proactive urinary tract supplement system to help maintain
urinary health. Earlier this year, Uqora launched three UTI
relief products
aimed at addressing concerns for those with active UTIs. These products include
diagnostic test strips so users can conclude
if they have a UTI, and two over-the-counter products for pain relief
and infection control. The introduction of these three new products means Uqora
products now tackle urinary tract infections end-to-end. Customers can turn to
Uqora for a proactive approach to urinary health , as well as diagnostics and
symptom relief so that they’re more prepared when visiting their health care
provider for UTI treatment. Over the last three years, Uqora has grown into a
one-stop-shop for Urinary tract health,, UTI diagnostics, and
relief. Growth in Research, Clinical TrialsAside
from expanding their product offerings, Uqora’s growth in funding has enabled
the company to launch several clinical
trials. These clinical trials with research groups Hawthorne Effect and the
George Washington University Medical Faculty Associates Urology Clinic will
test the efficacy of Uqora’s products. Both clinical trials will
expand research
for women’s urinary tract health, as well as help Uqora improve their product
offering, ensuring customers have the best preventative UTI products available.
Uqora has used its growth to further its mission to provide innovative and
effective alternative solutions for those who suffer from recurring UTIs. The
Hawthorne Effect clinical trial will take place over 180 days, with results
available in the second half of 2020. The George Washington University clinical
trial began in 2020 and will last 12 months. Both are randomized, double-blind,
placebo-controlled studies carried out by third-party labs, ensuring
trustworthy results. Without Uqora’s revenue growth and profitability, such
research would not be possible. Development of Non-Antibiotic TreatmentUTIs
are typically treated with antibiotics, despite the fact that the number of
antibiotic-resistant UTIs has doubled in the last 10 years. According to the
CDC, 30% of prescribed antibiotics are
unnecessary. Antibiotic resistance can also lead to a cycle of recurring
urinary tract infections. However, as public concern about antibiotic
resistance begins to grow, many are in search of effective alternatives. With
few answers outside of already established treatments, Uqora has been able to
capture a market ripe for innovation. This has allowed the company to continue
investing in research, testing its own products to ensure their effectiveness,
and growing its product offerings. Women’s
urinary health issues have long been underfunded and under-researched. Ryan
believes in the importance of contributing to scientific research involving
women’s health issues. It is this belief that motivates Uqora’s founders to
work towards creating options for those seeking UTI treatment alternatives.
Ever the leading innovators in the urinary tract health space, Uqora is working
to develop a new, non-antibiotic UTI treatment option for those seeking an
alternative to traditional antibiotic remedies.Uqora’s Innovative FutureUqora’s
impressive growth over the last three years has opened many avenues for the
young company. By prioritizing excellent customer service and providing
effective UTI solutions that lead to high customer retention rates, Uqora has
been able to expand its line of products, make strides in urinary health
research, and fund clinical trials. The company is also working to make
innovative strides in alternative UTI treatment solutions that address
antibiotic resistance. Uqora’s goal is to eventually develop an effective UTI
treatment option that does not require the use of antibiotics.Uqora
began out of necessity when Ryan was trapped in a recurring and painful UTI
cycle back in 2014. From that small founder and family funded venture, Uqora
has grown into a breakthrough biotechnology company, investing funding dollars
into women’s urinary health research and reimagining what it means to tackle
urinary tract health in a field where such research is often overlooked and
underfunded. As Uqora continues to grow, so will its reach and impact. Uqora
has already helped over 100,000 people struggling with recurring UTI
infections, and the company is still showing steady growth. Its emphasis on
research and development, paired with a mission to bring effective proactive
UTI prevention methods to all, makes Uqora a cutting-edge company to watch.
